Ralph A. J. G. Hamers
Management
Well, on leverage, we -- the question seems to be whether it will be at 4% in the Netherlands and we are at around that level, a little above it on an IFRS basis. So we don't see that the 4% leverage ratio will be a constraint for us going forward. In terms of dividend, you had a number of questions there. We said before that we have a willingness to return the net proceeds of insurance divestments to shareholders over time, and this will be part of a regular annual dividend discussion. As you recall, we've said before that the minimum is 40%. But at the end of the year, we'll look to see the lay of the land in terms of profit, economic development and also regulatory developments. But assuming on the basis that they are benign, we have a willingness to pay more than the 40% and return the churn surplus to shareholders over time. The -- and the timescale that we'll take, we're not going to be too prescriptive about it. The payout ratio would be somewhere between 40%, but not exceeding 100% of net profits, including the gains we currently see in the first quarter. Why not 100%? It could be 100%, because that's the point where you need to go to regulatory approval, and we refer to not have to do that. Although, with 100%, that gets quite a lot of fire burns, I mentioned already. So this will take a number of years to return this surplus to shareholders. We believe that a prolonged -- sustained, I should say, elevated dividend payout ratio is a better value proposition than potentially [ph] returning capital over a shorter timescale. And also, importantly, it does give us some protection in the event that the uncertain regulatory environment does change adversely, if you ask about the our target moving which, frankly, we don't know exactly how that [indiscernible]. It's still too much of a moving target to be prescriptive. But we have a significant capital surplus [ph] of the group. We would say, we are suppose to return the insurance surplus over time, but we want to keep an eye on how regulatory developments come. Obviously, you don't want to end up returning capital to shareholders and funding those regulatory change that was adverse. So we're going to be prudent in the return and keeping an eye on the regulatory capital developments.
Jean-Pierre Lambert - Keefe, Bruyette & Woods Limited, Research Division: And would you earmark some capital at the level of the bank going forward, surrender them, the upstreaming dividends, to the group?